==============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
-----------------------------------
DATE OF REPORT: June 20, 2002
DATE OF EARLIEST EVENT REPORTED: June 20, 2002
ICN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 1-11397 33-0628076
(State or other (Commission File Number) (I.R.S. Employer
jurisdiction of Identification Number)
incorporation or
organization)
3300 HYLAND AVENUE
COSTA MESA, CALIFORNIA 92626
(Address of principal executive offices)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (714) 545-0100
==============================================================================
Item 5. Other Events.
------------
On June 20, 2002, ICN Pharmaceuticals, Inc. (the "Company")
issued the press release attached as Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
---------------------------------
Exhibit Description
------- -----------
99.1 Press Release issued June 20, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on behalf of
the undersigned hereunto duly authorized.
Dated: June 20, 2002
ICN PHARMACEUTICALS, INC.
By: /s/ Gregory Keever
-----------------------------------------
Name: Gregory Keever
Title: Executive Vice President, General
Counsel and Corporate Secretary
EXHIBIT INDEX
Exhibit Description
------- -----------
99.1 Press Release issued June 20, 2002